Proposal of candidates to the Board of Directors
Please read the full announcement in PDF Attachment 2020_63_Proposal_of_candidates_to_the_Board_of_Directors
Staff
RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases
PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University...
OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics
Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of...
VitalHub Announces Addition of Award-Winning Synopsis iQ to Recently Expanded Multi-Year Licensing Deal with King’s College Hospital NHS Foundation Trust
TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...
Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive...
POINT Biopharma Announces New Board Appointments
Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) --...
CMR Surgical- Strong Commercial Progress in India and the Middle East
Strong Commercial Progress in India and the Middle East ·Versius has been adopted by a number of new hospitals, making...
Skylight Health Announces New OTCQX Ticker and Presentation at LD Micro in December
Skylight Health will begin trading under new ticker “SHGFF” on the OTCQX December 9, 2020Company continues to trade under “SHG”...
SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation
- SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension...
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
Event will review the company’s novel approach to inducing fetal hemoglobin Live webcast on December 15, 2020 at 8:30am ET...
Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit
- Presentation taking place today, December 9, 2020 at 10:50 AM ET TORONTO and HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE)...
Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study
Graphic 1 Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics,...
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company...
Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis
–Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores––EDP1815 first-ever candidate targeting SINTAX™ to...
Qu Biologics Completes $8M Financing
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site...
Evaxion Biotech Announces Publication in Nature Communications Describing Improved Selection of Immunotherapy Targets
COPENHAGEN, Denmark, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S, a clinical-stage AI-immunology company developing immunotherapies to improve the...
EU Boosts Evaxion’s Artificial Intelligence Vaccine Research
EIB signs €20 million (DKK 149 million) loan agreement with Danish research and development company Evaxion Biotech A/S.Evaxion will use financing for research...
Financial calendar 2021
Orphazyme A/SCompany announcement ...
Acarix announces the last patient included in Dan-NICAD II study
Press release Malmö, Sweden December 9, 2020 Acarix announces the last patient included in Dan-NICAD II study After the inclusion...
Covetrus Completes Separation from Former Parent Company
The Company Exits Final Transitional Services Agreement and Announces the Consolidation of its North American Commercial Organizations PORTLAND, Maine--(BUSINESS WIRE)--Covetrus...